Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Abdul Rahman Asif
These individualised treatments involve reprogramming immune cells to kill cancer. Within the new study, funded by charity Blood wise, the analysis team created a genetically built version of a cell referred to as associate degree invariant natural killer T-cell CAR19-I NKT. Current CAR-T therapies area unit terribly high-priced (around £300,000 per patient) and have a tendency to be made-to-order for every patient. However, scientists behind the present study say their newer CAR-T medical aid has the potential to be ten-fold cheaper and might be factory made to alter one batch to be used on multiple patients.
Published Date: 2021-03-31; Received Date: 2021-03-10